Triomics, a San Francisco-based healthcare startup, has recently secured $15 million in funding to revolutionize oncology workflows through the application of generative artificial intelligence (GenAI). The funding, led by prominent Silicon Valley investors such as Y Combinator, Lightspeed, General Catalyst, and Nexus Venture Partners, aims to propel Triomics’ mission of enhancing efficiency and patient care in cancer centers.
Triomics’ innovative technology harnesses the power of GenAI to automate tasks that are currently handled manually in cancer centers. By automating these processes, Triomics seeks to streamline workflows, thereby improving efficiency and ultimately enhancing patient care.
A key aspect of Triomics’ strategy is to pass costs directly to pharmaceutical sponsors whenever possible, thereby minimizing the financial burden on healthcare providers. Additionally, the company adopts performance-based agreements to ensure that partners realize a return on investment before incurring any out-of-pocket expenses.
Co-founded by Sarim Khan (CEO) and Hrituraj Singh (CTO), Triomics addresses a critical challenge in healthcare, particularly within oncology: the abundance of unstructured data in free-text patient records. Traditional methods of accessing this data, such as manual chart review, are time-consuming and inefficient, hindering crucial tasks like clinical research and patient care.
Triomics’ solution combines an oncology-focused large language model (OncoLLM) with custom software tailored for specific use cases. This combination enables automated data processing at scale, significantly reducing processing times. The company’s software suite includes Harmony, which facilitates EHR data curation for research and registry needs, and Prism, which streamlines patient-trial matching. Triomics also emphasizes continuous collaboration with partners to develop a future-proof product roadmap.
Triomics distinguishes itself from foundational model companies by specializing in oncology and developing software tailored for complex use cases within healthcare. Unlike competitors that rely on legacy technologies, Triomics offers scalability and cost-effectiveness in automating oncology workflows.
Triomics’ innovative approach to automating oncology workflows with generative AI holds significant promise for the future of cancer care. With a focus on explainability, user-centric design, and collaboration, Triomics is well-positioned to navigate the complexities of implementing AI in this critical domain.
